Safety study of VX-581 in healthy people
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests the safety of a new medicine called VX-581. It is given to healthy volunteers to see how the body processes the drug and if it causes any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult.
- You must have a body mass index (BMI) between 18.0 and 32.0.
- You must weigh more than 110 pounds (50 kg).
- You must not be able to become pregnant (if female, postmenopausal or surgically sterile).
- You must not have had a fever or other illness within the last 2 weeks.
- You must not have any condition that affects how your body absorbs medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational medicine called VX-272 in healthy volunteers. Researchers want to check its safety and how it moves through the body, so you would not have the condition the medicine is being developed for.
This Phase 3 study looks at how well and how safely Vanzacaftor/Tezacaftor/Deutivacaftor works over the long term in people with cystic fibrosis who already took the study medicine before. It may help confirm the best long-term plan and spot important safety issues.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.